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Summary. Background: Platelet induced thrombosis is a major risk factor for 
recurrent ischaemic events, although platelet function in patients with cardiovascular 
disease taking aspirin and clopidogrel is very poorly characterised. The aim of this 
study was to assess platelet reactivity in patients with cardiovascular disease taking 
aspirin and clopidogrel. 
Methods: We developed a rapid assay to measure platelet aggregation in response to 
arachidonic acid, collagen, adenosine diphosphate (ADP), epinephrine and Thrombin 
Receptor Activating Peptide (TRAP) in 80 healthy volunteers. We then recruited 200 
consecutive patients from outpatient clinics and the cardiac catheterisation laboratory 
and tested platelet function.  Platelet aggregation induced by epinephrine is a marker 
of global platelet reactivity. We tested platelet function in 146 patients compliant with 
antiplatelet therapy. Platelet aggregation to epinephrine was divided into quartiles. 
The platelet response to the other agonists was analysed based on the response to 
epinephrine.   
Results: Platelet reactivity increased significantly across the quartiles in response to 
epinephrine in normals and patients (p<0.0001). A significant increase in response 
across quartiles was seen with all agonists in normals (p<0.001). In contrast, a 
significant increase in response across quartiles was only seen with ADP in patients 
(p<0.0001). Hypertension, smoking and diabetes were significantly associated with 
increasing platelet reactivity to epinephrine (p < 0.05). 
Conclusion: This study shows that platelet response differs between normals and 
patients on dual antiplatelet therapy. Dual antiplatelet therapy unmasks a distinct type 
of platelet reactivity in response to epinephrine and ADP but not other agonists, in 
patients with cardiovascular disease. 
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Keywords: coronary artery disease, dual antiplatelet therapy, epinephrine, platelet 
aggregation, platelet reactivity. 
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Introduction 
 Platelets play a critical role in patients with cardiovascular disease [1]. 
Antiplatelet drugs are effective, both alone and in combination, in the secondary 
prevention of cardiovascular disease [2, 3]. However, platelet function in patients on 
dual antiplatelet therapy with cardiovascular disease is not fully understood [4]. 
Several lines of evidence suggest that recurrent thrombotic events may be due to 
increased platelet reactivity in patients taking aspirin and clopidogrel. Moreover 
increased platelet reactivity may predict risk for future cardiovascular events [5-7]. 
There is a growing body of evidence suggesting that platelet reactivity is important in 
clinical practice [8-10]. Platelet function is not measured routinely in clinical practice 
because it is labour intensive, expensive and time consuming. Moreover the direct 
clinical applicability of standard assays such as light transmission aggregometry in 
patients with cardiovascular disease is questionable [4, 11].  
Many assays of platelet function have been developed since light transmission 
aggregometry. Two of these, the PFA-100 ™ and the Verify Now ™, have advanced 
research in arterial thrombosis, especially in the area of monitoring antiplatelet 
therapy. The PFA-100 ™ has a major disadvantage, however, in that it is insensitive 
to monitoring the effect of clopidogrel and the Verify Now ™ device requires a 
separate cartridge for the assay of either aspirin or clopidogrel response, making it 
relatively expensive [12]. In addition, the role of these assays in the evaluation of 
platelet response to other agonists known to activate platelets is unclear.  
Normal volunteers who have the greatest platelet reactivity to epinephrine 
have platelets that aggregate more to other agonists as well. This has been termed 
global platelet hyperreactivity. It has been suggested that a common mechanism may 
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exist to explain the phenomenon of global platelet reactivity [13].  More recently, the 
phenomenon of  global hyperreactivity has been described in diabetic patients [6]. 
To understand platelet function in patients with cardiovascular disease taking 
dual antiplatelet therapy, we developed an assay that characterised the response to 
multiple agonists. We developed an assay that was rapid, inexpensive, and capable of 
assessing multiple platelet receptors and pathways simultaneously in patients on dual 
antiplatelet therapy. In contrast to normal volunteers and diabetics, we found that 
patients with cardiovascular disease on dual antiplatelet therapy have increased 
platelet reactivity in response to epinephrine and ADP alone.  This response does not 
generalise to the agonists collagen, arachidonic acid and TRAP in patients compliant 
with their antiplatelet medication. 
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Methods 
Patients 
 This study was approved by Medical Research Ethics Committees of both the 
Royal College of Surgeons and Beaumont Hospital and complied with the Declaration 
of Helsinki. Informed consent was obtained from all patients prior to phlebotomy. 
Healthy volunteers 
 To establish the normal range of platelet response, we tested 80 healthy 
volunteers (male=40, female=40) who had not taken any medication known to affect 
platelet function in the previous 14 days. Blood was drawn before 10 AM and 2 hours 
after a light breakfast to minimise variation due to circadian rhythm. Blood was 
collected through a 19-gauge Butterfly® needle into a 30-ml syringe containing 3.2% 
sodium citrate. The first 3ml of blood was discarded. Blood was centrifuged for 10 
min at 150g. Platelet-rich plasma (PRP) aspirated from the supernatant was placed in 
a reagent reservoir. Using a multi-channel pipette, the PRP was dispensed across 
wells in a 96-well plate (black isoplate ® with clear flat-bottomed wells, 
PerkinElmer) containing different concentrations of the agonists, arachidonic acid, 
collagen (type 1 soluble calf skin), Adenosine Diphosphate (ADP), epinephrine and 
Thrombin Receptor Activating Peptide (TRAP).  
Patients on dual antiplatelet therapy 
 Patients with cardiovascular disease were recruited from the cardiology 
outpatient clinic and the cardiac catheterisation laboratory. All patients taking dual 
antiplatelet therapy who had received 4 or more doses of aspirin and clopidogrel or 
patients who received an equivalent loading dose of 300 mg of aspirin and clopidogrel 
in the previous 24 hours were screened for eligibility. 
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Patients taking GPIIb/IIIa inhibitors, warfarin, non-steroidal anti-inflammatory 
medication or any other medication known to affect platelet function were excluded. 
Patients with a serum creatinine > 150 mmol/l, or a platelet count of < 100,000 / mm3, 
or who were pregnant, or had hepatic dysfunction (defined by hepatic enzymes more 
than twice the upper normal limit) were also excluded. After resting comfortably for 
at least 10 minutes, patients were phlebotomised and blood collected as described 
above. Demographic material was recorded on all patients. 
Assessment of Drug Compliance 
 A standard questionnaire was completed by each patient to review compliance 
with antiplatelet therapy. Patients were excluded if they stated or if they suspected 
that they had not taken their medication on one or more occasion(s) in the previous 14 
days. A significant response (≥20%) to arachidonic acid may indicate non compliance 
with antiplatelet therapy [14]. Therefore patients who demonstrated a platelet 
aggregation response of ≥20% to arachidonic acid were also excluded from this study.  
Finally, we compared the response to arachidonic acid between the inpatient and 
outpatient population as an index of compliance.  
Novel Platelet Function Assay 
 To assess platelet function, we used a modification of light transmission 
aggregometry that we have previously described [15, 16]. In brief, 180 µl of PRP was 
added to each well of a 96-well plate containing different agonists. Light absorbance 
was measured at standard times. Light absorbance values were then normalised based 
on the PRP and PPP absorbance values which represented 0 and 100% aggregation. 
Using this, the percentage aggregation response for each concentration of each agonist 
was calculated and plotted as dose response curves (Fig. 1). To characterise maximal 
platelet aggregation in healthy volunteers and coronary artery disease patients taking 
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dual antiplatelet therapy we assayed increasing concentrations of 5 different agonists 
using the same novel platelet function test. 
 Platelet aggregation measured as a percentage of absorbance from baseline 
using a 572 nm filter was assayed at 0, 3, 9, 15 and 18 minutes. Between each of the 
standardised times, the plate was rotated at 1000 r.p.m. through a 0.1 mm orbit. The 
agonists used were arachidonic acid, collagen, ADP, TRAP and pharmacological 
concentrations of epinephrine. The final concentrations of the agonists arrayed were 
(500, 375, 188, 93.8, 46.9, 23.4, 11.8, 5.86) µg/ml for arachidonic acid; (190, 143, 
71.3, 35.6, 17.8, 8.9, 4.45, 2.23) µg/ml for collagen; (20, 10, 5, 2.5, 1.25, 0.625, 
0.313, 0.156) µM for ADP and TRAP; and (20, 5, 1.25, 0.313, 0.078, 0.0195, 
0.00488, 0.00122) µM for epinephrine.  The agonist volumes used were 50 µl of 
arachidonic acid, 50 µl of collagen, 40 µl of ADP, 40 µl of epinephrine and 40 µl of 
TRAP. The 96-well plate was then read using a Victor 3™ Multilabel plate reader 
(Perkin Elmer, Wellesley, MA, USA). The time from blood draw until the end of the 
assay protocol was recorded.  
Statistical analysis 
 Continuous variables were analysed for a normal distribution using the 
Kolmogorov-Smirnov test (using p value > 0.2 as threshold). Continuous variables 
following a normal distribution are expressed as a mean value +/- standard deviation. 
Comparisons between quartiles were analysed using one-way ANOVA for continuous 
variables and the Cochran-Armitage trend test for categorical variables. Comparisons 
between inpatient and outpatient response to arachidonic acid were analysed using 
Fisher’s exact test. The nominal level of significance was 5% and multiple 
comparisons between quartiles were adjusted using the Bonferroni correction. 
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 To assess assay reproducibility, we calculated the inter-assay (between assay 
precision) and the intra-assay (within assay precision) coefficients of variation. The 
between assay precision was analysed using 10 normals measured on 5 separate 
occasions at least one week apart. A value of <12% for the between assay precision is 
regarded as acceptable for assay validation [17]. The within assay precision was 
analysed from the same donor in response to the same agonist measured 10 times on 
the same day.  
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Results 
 To develop an assay of platelet function that was rapid, reproducible and 
which defined the maximal response to different agonists, we assayed increasing 
concentrations of different agonists at multiple time points. Concentrations of the 
agonists, arachidonic acid and collagen, ranging from 2.23-500 µg/ml and the 
agonists, ADP, epinephrine, and TRAP, ranging from 0.00122-20 µM were assayed. 
We assayed these concentrations in PRP from 80 healthy volunteers (40 males and 40 
females). Since the time to maximal aggregation varies depending on the agonist 
used, aggregation was assessed at different time points until maximal aggregation 
occurred. Maximal aggregation was defined as no change in absorbance with 
incremental concentration of agonist at two consecutive time points. Maximal 
aggregation occurred at 18 minutes in response to 500 µg/ml of arachidonic acid, 190 
µg/ml of collagen, 20 µM for each of ADP, epinephrine and TRAP in all cases. The 
average time from blood draw to completion of the assay was 41 ± 6 minutes.  
 To establish the reproducibility of the test, the between and within assay 
precision of the assay were calculated. The between assay precision of each agonist 
was; for arachidonic acid 500mg/ml - 12%, collagen 190mg/ml - 10%, ADP 20 µM – 
8%, epinephrine – 11% and TRAP – 11%. The within assay precision was < 1% for 
all agonists, indicating excellent reproducibility. 
 Platelet reactivity was then tested in a cohort of patients taking antiplatelet 
agents. The assay detects the effect of aspirin alone and in response to aspirin and 
clopidogrel combined (supp Fig. 1S). A total of 200 consecutive patients with 
cardiovascular disease taking both aspirin and clopidogrel were screened from May 
2007 to July 2007 and their platelet function assayed. Demographic information for 
the patients is shown in Table 1.  
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Platelet reactivity in patients on dual antiplatelet therapy 
 Since non-compliance with aspirin therapy may confound interpretation of 
platelet function testing, we attempted to control for this in a number of ways. We 
excluded patients who stated that they had missed one or more doses of their 
antiplatelet therapy in the previous 14 days (26/200, 13%). Secondly, since an 
aggregation response of ≥20% to arachidonic acid may indicate non-compliance, we 
excluded patients whose aggregation response to arachidonic acid was ≥20% (28/200, 
14%). We then analysed the platelet data from the remaining 146 subjects. Since non-
compliance is more likely in the outpatient population compared to the inpatient 
population [18], we compared the response to arachidonic acid between these two 
groups. The relative proportions of patients with a response to arachidonic acid of 
≥20% between the inpatient and outpatient population were identical (supp Fig. 2S). 
Thus non-compliance seems unlikely to account for the results of our investigation.  
 Epinephrine has been shown to be a marker for global platelet reactivity in 
healthy volunteers [13]. Therefore we characterised platelet response to epinephrine 
in healthy volunteers and coronary artery disease patients on dual antiplatelet therapy. 
Overall the mean aggregation response to epinephrine was 80 ± 11% for the healthy 
volunteers. The mean aggregation response to epinephrine was 53 ± 16% in the 
patients; the response was highly variable in the patients and followed a normal bell 
shaped distribution. Platelet aggregation in response to submaximal concentrations of 
epinephrine (0.313µM) in healthy volunteers followed a bimodal distribution in 
agreement with previous work (Fig. 3S). In contrast there was no bimodal distribution 
in patients on dual antiplatelet therapy [13].  Platelet response variability was 
significantly higher in the patients compared to the healthy volunteers (p=0.0071) 
(supp. Fig. 4S). Platelet aggregation to 20 µM epinephrine was read at 18 minutes. 
Page 11 of 38 Journal of Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 12 
The maximal platelet aggregation response to epinephrine ranged from 16 - 80% in 
146 patients and was then ranked from the lowest to the highest responder and divided 
into quartiles. The mean percentage platelet aggregation in response to epinephrine in 
each of the quartiles was 32 ± 7%, 47 ± 4%, 60 ± 4% and 72 ± 4% (Fig. 2). The mean 
response between each quartile was significantly different (p<0.0001). When we 
analysed platelet response to submaximal concentrations of epinephrine we find that 
in healthy volunteers the response to epinephrine predicted a greater response to all 
agonists. In contrast in the patients taking dual antiplatelet therapy the response to 
epinephrine was only seen in response to ADP and not to any of the other agonists 
(supp. Fig. 5S A & B). Smoking, hypertension and diabetes significantly influenced 
platelet reactivity (p<0.05) across the epinephrine quartiles.  
 We evaluated the influence of cardiovascular risk factors on platelet reactivity 
using trend testing. The relative number of subjects with a history of diabetes mellitus 
significantly increased as the level of platelet reactivity increased when we based the 
quartiles on the response to either epinephrine or TRAP (p<0.05) but did not 
influence platelet reactivity when we based the quartiles on the response to ADP or 
collagen. Similarly, hypertension significantly influenced platelet reactivity across the 
quartiles in response to either epinephrine or TRAP (p<0.05) but did not influence 
platelet reactivity in the response to either ADP or collagen. The relative number of 
subjects with a history of smoking significantly increased as the level of platelet 
reactivity increased based on the response to epinephrine only (p<0.05). The other 
risk factors did not influence platelet reactivity. In addition, trend testing found no 
link between cardiovascular medications and platelet reactivity (Table 1). 
 As described above the aggregation response to epinephrine was ranked from 
the lowest to highest responder and divided into quartiles. The corresponding 
Page 12 of 38Journal of Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 13 
response to each agonist was then analysed for each individual within the original 
epinephrine quartiles.  
 The response to arachidonic acid was analysed for each individual within the 
original epinephrine quartiles. The mean platelet aggregation response for the entire 
cohort using arachidonic acid (500 µg / ml) was 8 ± 5% indicating that the TXA2 
pathway was adequately inhibited in this study population. The mean percentage 
platelet aggregation in response to arachidonic acid in each of the epinephrine 
quartiles was 7 ± 4%, 8 ± 5%, 8 ± 4% and 9 ± 5%. There was no significant 
difference between the quartiles in response to arachidonic acid (Fig. 3Α). The 
response to collagen was analysed for each individual within the original epinephrine 
quartiles. The mean platelet aggregation response for the entire cohort using collagen 
(190 µg/ml) was 64 ± 15%. The mean percentage platelet aggregation in response to 
collagen in each of the epinephrine qua tiles was 59 ± 17%, 67 ± 12%, 63 ± 16% and 
67 ± 14%. There was no significant difference between these quartiles in response to 
platelet aggregation induced by collagen (Fig. 3Β). 
 The response to TRAP was analysed for each individual within the original 
epinephrine quartiles. The mean platelet aggregation response for entire cohort using 
the agonist TRAP (20 µM) was 61 ± 12%. The mean percentage platelet aggregation 
in response to TRAP in each of the epinephrine quartiles was 57 ± 13%, 60 ± 10%, 62 
± 10% and 65 ± 13%. There was no significant difference between the quartiles in 
response to TRAP (Fig. 3C). 
 The response to ADP was analysed for each individual within the original 
epinephrine quartiles. The mean platelet aggregation response for the entire cohort 
using ADP (20 µM) was 40 ± 18%. The mean percentage platelet aggregation in 
response to ADP in each of the epinephrine quartiles was 30 ± 14%, 40 ± 19%, 39 ± 
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16% and 50 ± 15%. The second quartile in ADP response was significantly higher 
than the first and the fourth quartile was significantly higher than the third (p<0.01 
and p<0.005, respectively). In summary, platelet reactivity increased significantly 
across the quartiles in response to epinephrine (p<0.0001). This increasing linear 
trend was also observed in response to ADP (p<0.0001) but was not detected with the 
other agonists suggesting that there is a distinct platelet reactivity in response to both 
epinephrine and ADP  in patients with cardiovascular disease taking both aspirin and 
clopidogrel (Fig. 4). 
Page 14 of 38Journal of Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 15 
Discussion 
Platelets play a critical role in the pathogenesis of thrombosis in 
cardiovascular syndromes [19]. Several recent studies have identified variable platelet 
response in patients taking antiplatelet therapy [20-22]. However, platelet 
responsiveness in patients with coronary artery disease on dual antiplatelet therapy 
has not been well characterised. We developed an assay that could be preformed near 
the patient to assay platelet function in response to multiple agonists. Our assay is 
rapid with the average time from blood draw to results of platelet function being less 
than one hour. In detailed studies of normal healthy volunteers, Yee at al [13] have 
shown that platelet response to epinephrine predicts the response to other agonists, a 
term called “global platelet hyperreactivity”. The results of the present investigation 
demonstrate in coronary artery disease patients taking both aspirin and clopidogrel, 
that epinephrine elicits a markedly heterogeneous response. This response was also 
seen with the agonist ADP. In contrast, there was no variation in response to the 
agonists, arachidonic acid, collagen or TRAP. Thus the response of platelets in 
patients with coronary artery disease taking dual antiplatelet therapy is different from 
normal healthy volunteers.  
Compliance is a confounding variable in the assessment of patients on 
antiplatelet therapy. Indeed, it has been suggested that a lack of response to 
antiplatelet therapy may simply be explained by non-compliance [23]. To address the 
issue of compliance, all patients in this study were questioned in detail regarding their 
antiplatelet therapy. We excluded those individuals who had not taken their 
medication as prescribed in the previous 14 days. Arachidonic acid induced platelet 
aggregation of greater than or equal to 20% has been proposed as a definition of 
response to aspirin [14, 24-28]; however the definition of clopidogrel non-response 
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remains unclear [29, 30]. Since aspirin non-responsiveness may be due to non-
compliance, we also excluded patients from our study whose platelets had a response 
to arachidonic acid of ≥20%. It has been suggested that an analysis of platelet 
response to antiplatelet therapy in inpatient and outpatient groups should be 
performed in interpreting this type of study as antiplatelet therapy is better controlled 
in an inpatient setting [18]. Therefore, we compared the response to arachidonic acid 
between the inpatient and outpatient populations. We found no significant difference 
in the platelet response to aspirin between inpatients and outpatients. Thus it seems 
unlikely that our results may be attributed to non-compliance with therapy.  
In our investigation smoking, hypertension and diabetes significantly 
influenced platelet reactivity based on the response to epinephrine (p<0.05). This is in 
agreement with previous studies suggesting that these risk factors influence platelet 
reactivity [31-36]. Recent evidence from two studies examining platelet reactivity in 
normal volunteers and in patients with type II diabetes have demonstrated when a 
subject has increased platelet reactivity to one agonist that they have increased platelet 
reactivity to all agonists [6, 13]. These results are in marked contrast to the current 
study where patients on dual antiplatelet therapy had an increased response to only 
epinephrine and ADP. The reasons for this divergence are not readily apparent, but do 
not seem to be related to the drugs used in our population. It is interesting to speculate 
that the mechanisms of increased platelet reactivity in patients with coronary artery 
disease are different from both normal volunteers and type II diabetics. A unifying 
hypothesis that could explain the observed association between smoking, 
hypertension and platelet reactivity could be enhanced sympathetic activity. 
 There is a genetic component in coronary artery disease and in platelet 
reactivity in normal healthy volunteers [37, 38]. Recent work by Bray et al has 
Page 16 of 38Journal of Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 17 
demonstrated that a component of the platelet response seen in vitro in patients with 
coronary artery disease is at least in part mediated by genetic factors [39]. Whether 
our results are due to common environmental factors shared in this cohort of patients 
or genetic factors is unclear. The increased response to the agonists ADP and 
epinephrine in contrast to other agonists suggests a common pathway possibly 
through adenylate cyclase that could be modified by either genetic (hypertension) or 
environmental factors (smoking) in patients with coronary artery disease. This 
pathway warrants further investigation as a marker of potential risk for future 
thrombotic events in patients with coronary artery disease.  
 In summary, we have developed an assay that is rapid, inexpensive, and 
capable of assessing multiple platelet receptors and pathways simultaneously in 
patients on dual antiplatelet therapy. In contrast to normal volunteers and diabetics, 
we found that patients with cardiovascular disease on dual antiplatelet therapy have 
increased platelet reactivity in response to epinephrine and ADP alone, which does 
not occur in response to the agonists, collagen, arachidonic acid and TRAP, in 
patients with coronary artery disease compliant with their antiplatelet medication. In 
this study we observed substantial interindividual variability in response to 
epinephrine, more so in the patients compared to the healthy volunteers. Whether 
more aggressive antiplatelet therapy is warranted in this group remains to be 
determined. 
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Legends 
Table 1 Patient Demographic data  
Smoking, hypertension and diabetes significantly influenced platelet reactivity in 
response to epinephrine *(p < 0.05). PPI, proton pump inhibitor, ACS, acute coronary 
syndrome, ACE, angiotensin converting enzyme, AT-II, angiotensin II. 
Fig. 1. Dose response curves using 5 different agonists in 80 healthy volunteers. 
The curves represent aggregation responses to increasing concentrations of 
arachidonic acid, collagen, ADP, epinephrine and TRAP in 80 healthy volunteers. 
Each data point represents the mean aggregation (%) to each concentration plus or 
minus the standard error of the mean. 
Fig. 2. Maximal platelet aggregation in response to epinephrine is variable in the 
presence of dual antiplatelet therapy (*** p < 0.0001) 
Fig. 3. Increased platelet reactivity to epinephrine is not associated with 
increased platelet reactivity to arachidonic acid, collagen or TRAP 
Figures 3(A), (B) & (C) demonstrates a non-significant difference between each 
epinephrine quartile for the agonists, arachidonic acid, collagen and TRAP, 
respectively. ns, non-significant 
Fig. 4. Increased platelet reactivity to ADP is associated with increased platelet 
reactivity to epinephrine.  
The increasing linear trend seen in response to epinephrine is also seen in response to 
ADP (p < 0.0001). * p < 0.01, ns, non-significant, ** p < 0.005 
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 Entire 
cohort 
(n=146) 
1st 
Quartile 
(n=37) 
2nd 
Quartile 
(n=36) 
3rd 
Quartile 
(n=36) 
4th 
Quartile 
(n=37) 
 
p 
Value 
Age(yrs) 64±12 64±15 65±10 65±11 63±12 0.88 
Male, n (%) 94(64) 26(70) 23(64) 19(53) 26(70) 0.76 
Risk Factors: n (%) 
Diabetes 25(17) 5(14) 2(6) 8(22) 10(27) * 
Smoking history 107(73) 21(57) 28(78) 26(72) 32(86) * 
Hypertension 78(53) 17(46) 20(56) 22(61) 26(70) * 
Dyslipidaemia 96(66) 27(73) 21(58) 22(61) 26(70) 0.88 
Family History 71(48) 21(57) 12(33) 14(39) 24(65) 0.42 
Past Vascular disease 84(58) 24(65) 16(44) 23(64) 21(57 0.88 
ACS 71(48) 15(40) 17(47) 20(56) 19(51) 0.27 
Medications: n (%) 
PPI 99(68) 23(62) 20(56) 29(80) 27(73) 0.09 
β-Blocker 125(86) 31(84) 31(86) 31(86) 32(86) 0.75 
Statin therapy 137(94) 33(89) 35(97) 33(92) 36(97) 0.28 
ACE 77(53) 20(54) 20(55) 19(53) 18(49) 0.60 
AT-II 31(21) 7(19) 5(14) 10(28) 9(24) 0.32 
 
Smoking, hypertension and diabetes significantly influenced platelet reactivity in 
response to epinephrine * (p < 0.05). PPI, Proton Pump Inhibitor, ACS, Acute 
Coronary Syndrome, ACE, Angiotensin Converting Enzyme, AT-II, Angiotensin II. 
 
Table 1 Patient Demographic data  
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Fig. 1. Dose response curves using 5 different agonists in healthy volunteers. The curves represent 
aggregation responses to increasing concentrations of arachidonic acid, collagen, ADP, epinephrine 
and TRAP in 80 healthy volunteers. Each data point represents the mean aggregation (%) plus or 
minus the standard error of the mean.  
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Fig. 2. Maximal platelet aggregation in response to epinephrine is variable in the presence of dual 
antiplatelet therapy (*** p < 0.0001)  
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Fig. 3. Increased platelet reactivity to epinephrine is not associated with increased platelet reactivity 
to arachidonic acid, collagen or TRAP Figures 3(A), (B) & (C) demonstrates a non-significant 
difference between each epinephrine quartile for the agonists, arachidonic acid, collagen and TRAP, 
respectively. TRAP = Thrombin Related Activated Peptide, ns=non-significant  
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Fig. 4. Increased platelet reactivity to ADP is associated with increased platelet reactivity to 
epinephrine. The increasing linear trend seen in response to epinephrine is also seen in response to 
ADP (p < 0.0001). * p < 0.01, ns, non-significant, ** p < 0.005  
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Fig. 1S. The 96 well platelet function assay detects the effect of both aspirin and clopidogrel across 
all agonists. This demonstrates that aspirin inhibits platelet aggregation to the agonists, arachidonic 
acid, collagen, ADP, epinephrine and TRAP. The addition of clopidogrel leads to further platelet 
inhibition. ● normals n=80, ■ on aspirin n=93, ○ on aspirin and clopidogrel n=146  
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Fig. 2S. Platelet aggregation induced by arachidonic acid is the same in the inpatient and outpatient 
population Variation in response to antiplatelet therapy may be related to compliance. To address 
this we excluded those individuals with an aggregation response greater than 20%. To examine this 
further we determined whether the response to arachidonic acid varied in the outpatient versus the 
inpatient population and found that the relative proportion of patients was non-significantly 
different.  
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Fig. 3S. There is a bimodal distribution of aggregation in response to submaximal concentrations of 
epinephrine in healthy volunteers (n=80). This histogram depicts the number of subjects with a 
given level of aggregation to epinephrine at a concentration of 0.313µM.  
108x103mm (300 x 300 DPI)  
 
Page 32 of 38Journal of Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
  
 
 
Fig. 4S. There is wider variability in platelet responses to epinephrine in patients taking dual 
antiplatelet therapy compared to healthy volunteers. The aggregation response to the maximum 
concentration of epinephrine was plotted for healthy volunteers (n=80) and patients taking dual 
antiplatelet therapy (n=146). The interindividual variability was significantly wider in patients 
compared to healthy volunteers. ** p=0.0071.  
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Fig. 5S (A) & (B). Healthy volunteers demonstrate global hyperreactivity in contrast to patients on 
dual antiplatelet therapy. In healthy volunteers shown in panel (A) the response to epinephrine 
predicted a greater response to all agonists whereas in the patients taking dual antiplatelet therapy 
seen in panel (B) the response to epinephrine was only seen in response to ADP and not to the 
other agonists.  
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